{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:50Z","timestamp":1788052490919,"version":"build-2784847793"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108247","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:11:29Z","timestamp":1783365089000},"page":"108247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive\/HER2-negative breast cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"I.","family":"Schlam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-3487","authenticated-orcid":false,"given":"H.","family":"Heiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4028-2588","authenticated-orcid":false,"given":"P.","family":"Sanz-Altamira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Battelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-1570","authenticated-orcid":false,"given":"S.","family":"Berwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-8552","authenticated-orcid":false,"given":"L.","family":"Varella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-5727","authenticated-orcid":false,"given":"P.D.","family":"Poorvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"N.","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-8957","authenticated-orcid":false,"given":"E.L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.esmoop.2026.108247_bib1","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108247_bib2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study","volume":"32","author":"Harbeck","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108247_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108247_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108247_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108247_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108247_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.annonc.2025.09.141","article-title":"TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive\/HER2-negative breast cancer","volume":"37","author":"Mayer","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108247_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","article-title":"Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument","volume":"15","author":"Brady","year":"1997","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108247_bib9","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108247_bib10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaoncol.2025.3700","article-title":"Ribociclib plus endocrine therapy in hormone receptor-positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial","volume":"11","author":"Fasching","year":"2025","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108247_bib11","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108247_bib12","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108247_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.108247_bib14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.esmoop.2026.108247_bib15","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108247_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-024-00639-1","article-title":"Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study","volume":"10","author":"Goetz","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"12_suppl","key":"10.1016\/j.esmoop.2026.108247_bib17","first-page":"P1-11","article-title":"Abstract P1-11-16: Impact of ribociclib dose reduction on efficacy in patients with hormone receptor\u2013 \u201cpositive\/human epidermal growth factor receptor 2\u2013negative (HR+\/HER2\u2212) early breast cancer (EBC) in NATALEE\u201d","volume":"31","author":"Hamilton","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4_suppl","key":"10.1016\/j.esmoop.2026.108247_bib18","first-page":"GS1","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA breast cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926021897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:05:42Z","timestamp":1785974742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926021897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926021897"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108247","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive\/HER2-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108247"}}